Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H: quinone oxidoreductase (NQO1) and is utilized in anticancer research.

Isobutyl-deoxynyboquinone (0.01~100 μM; OSCC cells) demonstrates greater cytotoxic potency against SCCF1 and SCCF2 cell lines, and less against the SCCF3 cell line. Isobutyl-deoxynyboquinone (0.1~3 μM; 60 minutes; SCCF1 cells) induces cytotoxicity in a dose-dependent manner[1].

Isobutyl-deoxynyboquinone (0.5~2 mg/kg; i.v.; 20 hours) achieves average peak plasma concentration levels. Isobutyl-deoxynyboquinone (1 mg/kg; p.o.; 4 hours) achieves peak plasma concentrations[1]. Animal Model: Cats Dosage: 0.5~2 mg/kg (Pharmacokinetic Analysis) Administration: I.v. Result: Achieved average peak plasma concentration levels. Animal Model: Cats Dosage: 1 mg/kg (Pharmacokinetic Analysis) Administration: P.o. Result: Achieved peak plasma concentration.